Skip to content
  • menu secondaire

    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts
    • Profile
      • About Transgene
      • Management Team
      • Board of Directors
      • Corporate governance
      • Ethics & compliance
      • Collaborations
      • Partners
    • Technology
      • Viral-based Immunotherapies
        • Therapeutic Vaccines
        • Oncolytic Viruses
      • myvac Platform
      • Invir.IO Platform
      • Publications and Presentations
    • Portfolio
      • Pipeline
      • TG4050
      • TG4001
      • TG6002
      • TG6050
      • BT-001
      • Clinical trials FAQ
    • Press Releases
    • French

    Category: Webcast

    2022 Half-year results and business update

    link to webcast lien

    Published 7 September 2022
    Categorized as Press release, TG4001, TG4001, Webcast, Webcast, Webcast, Webcast

    License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Invir.IO™ Platform

    License Option Exercise by AstraZeneca

    Published 15 December 2021
    Categorized as Press release, TG4001, TG4001, Webcast, Webcast, Webcast, Webcast

    TG4050, First positive clinical data from Phase I clinical trials

    link to webcast

    Published 23 November 2021
    Categorized as Webcast, Webcast

    Half-Year results 2021 & Business Update

    lien

    Published 22 September 2021
    Categorized as Press release, TG4001, TG4001, Webcast, Webcast

    2021 Full-year results and business update

    link to webcast

    Published 16 March 2021
    Categorized as Press release, TG4001, TG4001, Webcast, Webcast, Webcast, Webcast

    Full Year Results 2020, Business Update & Update on the clinical development plan of TG4001

    Link to the webcast

    Published 10 March 2021
    Categorized as Webcast, Webcast

    Results from Phase 1b/2 Study of TG4001 with Avelumab in Advanced HPV-Positive Cancers

    https://channel.royalcast.com/webcast/transgene/20200722_1/

    Published 22 July 2020
    Categorized as Webcast, Webcast

    First efficacy results of TG4001+avelumab in HPV16-positive cancers

    https://channel.royalcast.com/webcast/transgene/20191003_1/

    Published 3 October 2019
    Categorized as Webcast

    Transgene and Tasly Biopharmaceuticals conclude strategic agreements for the rights of TG6002 and TG1050 in Greater China

    Webcast

    Published 10 July 2018
    Categorized as Uncategorized, Webcast
    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts

    Transgene sa
    400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
    67405 Illkirch Graffenstaden Cedex - France |
    Tel. : + 33 (0) 3 88 27 91 00

     

    © 2021 Transgene - All rights reserved
    Credits

    This Website uses cookies to provide you with the most relevant experience. By clicking on the "Accept All" button, you agree to the deposit of all cookies on your terminal. You can change your preferences or withdraw your consent at any time by clicking on the "Settings" button.
    More informationSettings Decline all ACCEPT ALL
    Cookies

    Privacy Overview

    This website uses cookies to improve your experience while you browse the website. Of these, cookies categorized as necessary are stored on your browser as they are essential for the functioning of basic functionalities of the website. We also use third-party cookies which advise us to analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the option of deactivating these cookies. But disabling some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously. Analytical cookies used to understand how visitors interact with the website.
    Functional (video)
    Functional cookies help to perform certain functions such as sharing website content on social media platforms, collecting feedback and other third-party functionality.
    Third-party application cookies (twitter)
    Cookies déposés par des sociétés autres que Transgene. Ces cookies sont susceptibles de transmettre aux sociétés tiers des informations en lien avec les pages consultées. Ces sociétés doivent s’engager à garder ces données confidentielles dans le cadre de la loi informatique et libertés (6 janvier 1978).
    Save & Accept
    Powered by CookieYes Logo